Does minimally invasive surgical thermal ablation improve safety for patients with colorectal liver metastases?
Minimally invasive surgical thermal ablation (MITA) is a treatment option for colorectal liver metastases (CLM) that uses heat (radiofrequency or microwave) to destroy tumors. It is performed laparoscopically or robotically, avoiding large incisions. The key question is whether this approach is safer than other treatments. Evidence from large studies shows that MITA has a low risk of major complications and very low short-term mortality, making it a safe option, especially for tumors that are difficult to treat with percutaneous (needle through skin) ablation.
What the research says
A systematic review and meta-analysis of 28 studies including 3,983 patients (most with CLM or hepatocellular carcinoma) found that MITA had a major complication rate (Clavien-Dindo grade 3 or higher) of only 2.2% and a 30-day mortality of 0.25% 35. These numbers are very low, indicating that MITA is a safe procedure. The same analysis reported a technical failure rate of 2%, which improved to 1% in studies published after 2017, showing that the technique has become more reliable over time 35. For CLM specifically, 1-year overall survival after MITA was 90%, and 5-year overall survival was 43% 35. Another review comparing local treatments for liver metastases noted that surgical resection has higher complication rates, while thermal ablation (including MITA) offers a less invasive option with good local control for tumors smaller than 3 cm 4. While MITA is safe, it is important to note that local tumor progression (recurrence at the ablation site) can occur, with an incidence rate of about 6 per 100 person-years 35. This means that while the procedure is safe, long-term follow-up is needed to monitor for recurrence.
What to ask your doctor
- Is my liver tumor suitable for minimally invasive surgical thermal ablation (MITA) instead of percutaneous ablation or surgery?
- What is the expected risk of major complications and mortality with MITA in my case?
- How does the long-term local control rate of MITA compare to other treatments for my specific tumor size and location?
- Will I need imaging follow-up after MITA to check for local tumor progression, and how often?
- Are there any specific factors (like tumor near large blood vessels) that might make MITA less safe or effective for me?
This question is drawn from common patient questions about Gastroenterology and answered using cited medical research. We do not provide individualized advice.